[Clinical efficacy and safety of itraconazole injection/oral solution sequential therapy for treatment of invasive fungal infection in intensive care unit].
To investigate the therapeutic efficacy and safety of itraconazole injection/oral sequential therapy on invasive fungal infection (IFI) in ICU. In this multicenter, post-marketing, open-label study, ICU patients who have met the inclusion IFI criteria will be enrolled in this study. Itraconazole intravenous injection is administered 200 mg twice a day in day 1 - 2, then 200 mg once a day at least for 5 days, and maintenance itraconazole oral solution as sequential therapy, itraconazole oral solution 200 mg twice a day sequential therapy lasts for 2 weeks. Clinical efficacy and adverse reaction were record. A total of 159 patients were enrolled and completed this trial. (1) At the end of first week, total clinical cure rate was 35.2%, and increased to 73.6% after the second week. Clinical cure rate were 72.9% and 72.2% in possible and probable IFI patients, and 78.9% in proven IFI patients at the end of second week. (2) At the end of first week, total fungal clearance was 40.9%, and increased to 75.9% and 92.9% at the end of second and fourth week. Fungal clearance were 90.0% and 64.6% in possible and probable IFI patients, and 84.2% in proven IFI patients at the end of second week respectively. (3) Combined clinical cure rate and fungal clearance, the total clinic efficacy was 44.1% at the end of first week, and increased to 92.9% and 100.0% at the end of second and fourth week. (4) No severe adverse reaction was found. Itraconazole injection/oral sequential therapy is an effective and safe antibiotic for the treatment of IFI in ICU.